Crohn’s  Colitis Foundation Perspectives

Crohn’s Colitis Foundation Perspectives

By ReachMDMedicine
Download on the App Store

Crohn’s Colitis Foundation Perspectives episodes

  • Iron Sequestration in Microbiota Biofilms in Treatment for IBD
    Host: Damian Maseda, D.M.Sc., PhD

    Iron Sequestration in Microbiota Biofilms As A Novel Strategy for Treating Inflammatory Bowel Disease.

    Jean-Paul Motta, PhD Thibault Allain, PhD Luke E Green-Harrison, BScRyan A Groves, MSc Troy Feener, MSc Hena Ramay, PhD Paul L Beck, MD/PhDIan A Lewis, PhD John L Wallace, PhD Andre G Buret, PhD

    ABSTRACT:

    Significant alterations of intestinal microbiota and anemia are hallmarks of inflammatory bowel disease (IBD). It is widely accepted that iron is a key nutrient for pathogenic bacteria, but little is known about its impact on microbiota associated with IBD. We used a model device to grow human mucosa-associated microbiota in its physiological anaerobic biofilm phenotype. Compared to microbiota from healthy donors, microbiota from IBD patients generate biofilms ex vivo that were larger in size and cell numbers, contained higher intracellular iron concentrations, and exhibited heightened virulence in a model of human intestinal epithelia in vitro and in the nematode Caenorhabditis elegans. We also describe an unexpected iron-scavenging property for an experimental hydrogen sulfide-releasing derivative of mesalamine. The findings demonstrate that this new drug reduces the virulence of IBD microbiota biofilms through …

    6 min
  • Diet Nutrition in the Management of IBD
    Host: Lu Ann Cahn
    Guest: James D. Lewis, MD, MSCE

    Whether they’re not getting enough calories or not eating a balanced diet due to disease restrictions, patients with IBD often have difficulty maintaining a healthy diet. So how can you help them navigate these diet and nutrition challenges?

    Filmed live at the 2018 Crohn's and Colitis Evening of Hope, Dr. James Lewis from the University of Pennsylvania discusses strategies you can implement in your practice.

    10 min
  • Emerging 'Bowel-Sparing' Procedures for Crohn's Disease
    Host: Jennifer Caudle, DO
    Guest: Fabrizio Michelassi, MD

    As a gastrointestinal surgeon and Chairman of Surgery at Weill Cornell, Dr. Fabrizio Michelassi has witnessed the possible complications that can stem from Crohn's disease. He joins Dr. Jennifer Caudle to provide his perspective on new surgical approaches to treat strictures and fibrostenotic complications.

    11 min
  • Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by MR Enterography
    Guest: Yash Mittal, MD

    Reliability of Measuring Ileo-Colonic Disease Activity in Crohn's Disease by Magnetic Resonance Enterography.

    Vipul Jairath, MD, PhD, Ingrid Ordas, MD, PhD, Guangyong Zou, PhD, Julian Panes, MD, Jaap Stoker, MD, PhD, Stuart A Taylor, MD, Cynthia Santillan, MD, Karin Horsthuis, MD, Mark A Samaan, MD, Lisa M Shackelton, PhD, Larry W Stitt, MSc, Pieter Hindryckx, MD, PhD, Reena Khanna, MD, William J Sandborn, MD ,Geert D'Haens, MD, PhD, Brian G Feagan, MD, Barrett G Levesque, MD, and Jordi Rimola, MD, PhD

    BACKGROUND:

    Magnetic resonance enterography is increasingly utilized for assessment of luminal Crohn's disease activity. The Magnetic Resonance Index of Activity and the London Index are the most commonly used outcome measures in clinical trials. We assessed the reliability of these indices and several additional items.

    METHODS:

    A consensus process clarified scoring conventions and identified additional items based on face validity. Four experienced radiologists evaluated 50 images in triplicate, in random order, at least 1 month apart, using a central image management system. Intra- and interrater reliability were assessed by calculating and comparing intraclass correlation coefficients.

    RESULTS:

    Intrarater intraclass correlation coefficients (95% confidence intervals) for the Magnetic Resonance Index of Activity, London, and London "extended" indices and a visual analogue …

    5 min
  • Success of Adalimumab Dose Escalation De-Escalation in Ulcerative Colitis
    Guest: Shail M. Govani, MD, MSc

    Incidence and Predictors of Success of Adalimumab Dose Escalation and De-escalation in Ulcerative Colitis: a Real-World Belgian Cohort Study.

    Saartje Van de Vondel, MD, Filip Baert, MD, PhD, Christine Reenaers, MD, PhD, Stijn Vanden Branden, MD, Leila Amininejad, MD, Pieter Dewint, MD, PhD, Wouter Van Moerkercke, MD, Jean-François Rahier, MD, PhD, Pieter Hindryckx, MD, PhD, Peter Bossuyt, MD, Marc Ferrante, MD, PhD, and Belgian IBD Research and Development (BIRD)

    BACKGROUND:

    Adalimumab (ADM) has been shown efficacious in ulcerative colitis (UC). In randomized controlled trials, dose escalation from 40 mg ADM every other week to 40 mg every week was required in 20%–25% of patients within 1 year. Real-life data suggest higher escalation rates. Attempts for dose de-escalation have not been studied yet. We assessed the need for, outcome of, and predictors of dose escalation and de-escalation in a large retrospective cohort of UC patients treated with ADM.

    METHODS:

    We included 231 consecutive patients from 10 Belgian centers initiating ADM treatment for active UC before September 1, 2015 (follow-up ≥1 year in each patient). We performed detailed chart review to identify variables associated with short-term clinical benefit (based on physician global assessment and absence of rectal bleeding at week 10), success …

    4 min
  • IBD Patient Management: Professional Education at Your Fingertips
    Host: Jennifer Caudle, DO

    With no cure for inflammatory bowel disease, or IBD, currently available, educating healthcare professionals and their patients on the best ways to manage IBD is essential. That’s why the Crohn’s & Colitis Foundation created training programs as part of their mission to eradicate these painful diseases, and here to talk more about these resources and programs with Dr. Jennifer Caudle is Michael Osso, President & CEO of the Crohn’s & Colitis Foundation.

    7 min
  • IBD: A Journey from Parent to Advocate
    Host: Jennifer Caudle, DO

    For many IBD patients and their parents, becoming involved with advocacy groups provides an excellent support system, especially since this can be a difficult disease to manage. But some also use these groups to make a difference not only locally, but also nationally.

    Sharing his personal-turned-professional journey with Dr. Jennifer Caudle is Frank Russomano, President and CEO of ReachMD, who is also joined by the President & CEO of the Crohn’s & Colitis Foundation, Michael Osso.

    9 min
  • What IBD Professionals can Expect from the 2019 Annual Crohn’s Colitis Congress

    The Crohn’s & Colitis Foundation, in partnership with the American Gastroenterological Association, will hold their 2nd Annual Congress from February 7 - 9, 2019 at the Bellagio Hotel in Las Vegas. To give you an inside look into the premier meeting for all IBD professionals and researchers, here’s a special message from Michael Osso, President & CEO of the Crohn’s & Colitis Foundation.

    For more information and to register, please go to: www.crohnscolitiscongress.org.

    1 min
  • The Art of Asking Patients for a Review
    Host: Randall Wong, MD
    Host: Russell Faust, MD

    Gone are the days when asking for reviews seemed desperate or unprofessional. Now it is much more acceptable, and in fact, patients expect it! Join Drs. Russ Faust and Randy Wong as they explain the importance of getting past the embarrassment and asking patients for reviews.

    0 min

About Crohn’s Colitis Foundation Perspectives

From the publisher's feed

As research in inflammatory bowel diseases (IBD) advances, the landscape is rapidly evolving; requiring reinforcement of the most important and clinically relevant data. This educational series will provide the latest information on research, treatments, and management of IBD with a focus on the most pressing and relevant topics identified by the Crohn’s Colitis Foundation's National Scientific Advisory Committee on Crohn’s Disease and Ulcerative Colitis.